



TML: CS: 2021-22

15<sup>th</sup>February, 2022

Listing Department,  
**BSE Limited**,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Listing Department,  
**National Stock Exchange of India Ltd.**  
"Exchange Plaza",  
Bandra – Kurla Complex,  
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

**Sub: Media Release - Financial Results for the third Quarter ended 31<sup>st</sup> December 2021.**

**Ref:** 1. BSE Scrip Code: 530199

2. NSE Scrip Code: THEMISMED

Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Media Release issued by the Company on its financial results for the third quarter and nine months ended 31<sup>st</sup> December 2021.

This is for your information and records.

Thanking you,

Yours Faithfully,  
For **Themis Medicare Limited**,



**Sangameshwar Iyer**  
**Company Secretary & Compliance Officer**

Encl: a/a

## **Themis Medicare Limited**

**Corporate Office :** 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104, India

**Tel. :** 91-22-6760 7080 • **Fax :** 91-22-6760 7070 / 2874 6621

**Regd. Office :** Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.

**CIN No.:** L24110GJ1969PLC001590 • **Tel / Fax No.:** **Regd. Off. :** 0260 2431447 / 2430219

• **E-mail :** themis@themismedicare.com • **Website :** www.themismedicare.com



## Media Release

**9M FY22 Revenue at Rs. 314.82 crore**

**9M FY22 EBITDA at Rs. 81.23 crore**

**9M FY22 EBITDA Margin at 25.80 %**

**9M FY22 PAT at Rs 62.93 crore**

### **Continued Focus on Complex Generics and Injectables driving performance**

**Mumbai, 11 February 2022:** Themis Medicare Limited (BSE: 530199 NSE: THEMISMED), Incorporated in 1969, is one of the fastest growing pharma Company specializing in the complex generics & injectables with a diversified portfolio of products spread across various segments with a strong focus & leadership in pain management and critical care areas. The Company has announced its unaudited financial results for the third quarter and nine months ended December 31st, 2021.

#### **Key Consolidated Financials (Rs. Crore): -**

Particulars	Q3 FY22	Q3 FY21	Y-o-Y	Q2 FY22	9M FY22	9M FY21	Y-o-Y
Revenue from Operations	94.92	65.52	44.88%	107.39	314.82	168.90	86.40%
EBIDTA (excl. Other Income)	17.29	15.25	13.40%	23.46	81.23	37.24	118.10%
EBITDA%	18.22%	23.28%		21.85%	25.80%	22.05%	
PAT	12.46	11.76	5.90%	19.28	62.93	27.65	127.60%
Basic EPS (Rs.)	13.54	12.80	5.78%	20.95	68.41	30.09	127.35%

#### **Performance Highlights: -**

##### **For the quarter ended December 31st, 2021:**

•Revenue from Operations stood at Rs. 94.92 crore in Q3 FY22, as against Rs. 65.52 crore in Q3 FY21, growth of over 44.88% - driven by increase in both Formulations and APIs

•EBITDA for the quarter was Rs. 17.29 crore as against Rs. 15.25 crore in Q3 FY21, increase of 13.40% - EBITDA Margin stood at 18.22% as against 23.28% for respective quarters - mainly on account of higher Raw Material prices and Higher processing charges



## Themis Medicare Limited

- Q3 FY22 Profit stood at Rs. 12.46 crore as against profit of Rs. 11.76 crore in Q3 FY21, increase of 5.90%

### **For the nine months ended December 31st, 2021:**

- Revenue from Operations stood at Rs. 314.82 crore in 9M FY22, as against Rs. 168.90 crore in 9M FY21, growth of 86.40%
- EBITDA stood at Rs. 81.23 crore as against Rs. 37.24 crore in 9M FY21, increase of 118.10% - EBITDA Margin stood at 25.80% as against 22.05% for respective periods
- 9M FY22 Profit stood at Rs. 62.93 crore as against profit of Rs. 27.65 crore in 9M FY21, increase of 127.60%
- Exports sales for 9M FY22 stood at 48% of total revenue as against 41% in 9M FY21

### **Management Comment:**

Commenting on the result, **Dr. Sachin D. Patel, MD and CEO, Themis Medicare** said,

*"I am happy to state that the Company produced a very satisfactory performance for the 9-month ended December 21. The continued focus on Formulations along with efforts to strengthen our exports presence enabled us to maintain momentum of growth for the Company.*

*Formulations sales for 9 months stood at nearly 70% and Exports sales were nearly 48%. Both these remain our strategic areas of growth. However, increasing Raw Material prices have been a pain area for us during the third quarter which also impacted the 9-month performance. Other Expenses too impacted the EBITDA performance for the quarter on account of higher processing charges.*

*We nevertheless remain confident of the growth momentum for the Company as our strategies continue to pay off. As stated earlier we are focused on growing our Complex generics portfolio with a strong focus on injectables. We also are focusing on increasing the NDDS basket of the Company. We are committed to build an ecosystem with multipronged strategies that would result in sustainable growth and profitability.*

*I take this opportunity to thank my entire team for working tirelessly and all stake holders for their continuous faith in this Company."*



## Themis Medicare Limited

### **About Themis Medicare Ltd.**

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma company specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug-delivery systems, the Company has evolved into being a formidable player in the complex generics space.

It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs – 1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectables portfolio and develop its NDDS presence.

**For more details, please visit: [www.themismedicare.com](http://www.themismedicare.com)**

<p>Company:</p> <p><b>Mr. Sangameshwar Iyer</b></p> <p>Company Secretary</p> <p><b>Themis Medicare Ltd.</b></p> <p>Email: sangameshwar.iyer@themismedicare.com</p>	<p><i>Investor Relations:</i></p> <p><b>Mr. Amit Sharma / Ms. Disha Shah</b></p> <p><b>Mob.: 9867726686 / 9699060134</b></p> <p><b>Bridge Investor Relations Pvt. Ltd</b></p> <p>Email: amit@bridge-ir.com / disha@bridge-ir.com</p>
--	--

### **Caution Concerning Forward- Looking Statements:**

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*